Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A project led by Professor Hugh Watkins at the Radcliffe Department of Medicine is one of the four projects on the shortlist of four research projects competing for a single £30 million award from the British Heart Foundation.

© Credit: University of Oxford, Dr P.Hales/BBSRC

The charity says it is one of many radical new approaches needed to address a frightening mismatch in research funding compared with the burden of heart and circulatory diseases.

With the World Health Organization forecasting an increase in cardiovascular deaths worldwide, the charity’s Big Beat Challenge is a global initiative to galvanise researchers and inspire transformational solutions to tackle the world’s biggest killer.

Professor Watkins' project aims to develop a cure for genetic heart muscle diseases which affect about 160,000 people in the UK, and about one million in the US. These cardiomyopathies affect the heart muscle, and are the leading cause of sudden cardiac death and heart failure in young people. While treatments to manage the symptoms of the disease exist, there is no cure for the root cause. 

Read more on the Radcliffe Department of Medicine website

Similar stories

Human challenge trial launches to study immune response to COVID-19

Clinical Trials Coronavirus COVID-19 General

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.